Clinical trials: Clinical Trial, Phase I
HIV-1 Infections
A Safety Study of Two Dapivirine (TMC120) Vaginal Gels in the United States
A double-blind, randomized, placebo-controlled Phase I/II trial to evaluate the safety of dapivirine Gel 4759, 0.05% 2.5 g and dapivirine Gel 4789, 0.05% 2.5 g formulations as compared to the vaginal HEC-based Universal placebo…
- Trial name
- NCT00799058
- Testing
- dapivirine 4789, dapivirine gel 4759
- Where
- 5 sites in United States
- Volunteers
- 128 people, healthy volunteers welcome
- Sponsor
- International Partnership for Microbicides, Inc.
Carcinoma, Hepatocellular
A Phase I / II Trial of Nintedanib in Asian Hepatocellular Carcinoma Patients
This study is to evaluate the safety, appropriate dose, and efficacy of BIBF 1120 in liver cancer patients
- Trial name
- NCT00987935
- Testing
- Sorafenib, BIBF 1120
- Where
- 16 sites in South Korea, Taiwan
- Volunteers
- 134 people
- Sponsor
- Boehringer Ingelheim
Evaluate the Safety and Tolerability, Healthy and Overweight or Obese Participants
Phase 1 Study of Ascending Doses of CMS-D008 in Healthy and Overweight/Obese Adults
This study is a first-in-human clinical trial of CMS-D008 conducted in Chinese healthy and overweight or obese adult participants, consisting of three parts: Part-1 Single Ascending Dose (SAD) study (hereinafter referred to as…
- Trial name
- NCT07518589
- Testing
- CMS-D008
- Volunteers
- 110 people, healthy volunteers welcome
- Sponsor
- Shenzhen Kangzhe Biotechnology Co., Ltd.
Tuberous Sclerosis, Angiofibroma
Phase III Trial of Topical Formulation of Sirolimus to Skin Lesions in Patients With Tuberous Sclerosis Complex (TSC)
The purpose of this trial is to evaluate the efficacy and safety of NPC-12G gel (topical formulation of sirolimus) versus placebo gel to facial angiofibroma and other skin lesions in patients with tuberous sclerosis complex (TSC)
- Conditions
- Tuberous Sclerosis, Angiofibroma, Hypomelanotic Macule, Plaque
- Trial name
- NCT02635789
- Testing
- NPC-12G gel
- Where
- Japan
- Volunteers
- 62 people
- Sponsor
- Nobelpharma
Breast Cancer
Temsirolimus Plus Neratinib for Patients With Metastatic HER2-Amplified or Triple Negative Breast Cancer
This is an open-label, single arm, multi-center, multi-national, adaptive design, dose-escalation Phase 1/2 study to determine the maximum tolerated dose (MTD) of temsirolimus with daily neratinib, and to determine the safety and…
- Trial name
- NCT01111825
- Testing
- Temsirolimus, Neratinib
- Where
- 12 sites in United States, Denmark and 4 more
- Volunteers
- 99 people
- Sponsor
- Puma Biotechnology, Inc.
Liver Cirrhosis
Safety and Efficacy Study of Umbilical Mesenchymal Stem Cells for Liver Cirrhosis
Liver cirrhosis and subsequent liver failure are leading causes of morbidity and mortality worldwide. Alcohol abuse and viral hepatitis are the most common causes of cirrhosis.
- Trial name
- LC (NCT01573923)
- Testing
- mesenchymal stem cells, Conventional therapy
- Where
- 6 sites in China
- Volunteers
- 320 people
- Sponsor
- Alliancells Bioscience Corporation Limited
Healthy
Pharmacokinetics and Safety Following Administration of DWP16001
To compare and evaluate the safety and pharmacokinetic characteristics after administration of DWP16001 Drug A and DWP16001 Drug B in healthy adult volunteers
- Trial name
- NCT05414591
- Testing
- DWP16001 drug A, DWP16001 drug B
- Where
- South Korea
- Volunteers
- 38 people, healthy volunteers welcome
- Sponsor
- Daewoong Pharmaceutical Co. LTD.
Healthy
A Phase I Clinical Trial to Investigate the Safety, Tolerability, and Pharmacokinetic Characteristics of TT-01025-CL in Healthy Subjects
To assess the safety, tolerability and pharmacokinetic characteristics of TT-01025 in healthy male subjects
- Trial name
- NCT04730050
- Testing
- TT-01025-CL
- Where
- United States
- Volunteers
- 64 people, healthy volunteers welcome
- Sponsor
- LG Chem
Partial-onset Seizures With or Without Secondary Generalisation
Clinical Trial for Zebinix (Eslicarbazepine Acetate) in Healthy Korean and Caucasian Adult
A dose randomized, double-blind, placebo controlled, single and multiple dosing, dose-escalation phase I clinical trial to investigate the safety, tolerability and pharmacokinetic characteristics of Zebinix (Eslicarbazepine…
- Trial name
- NCT04095182
- Testing
- Zebinix 400mg, Zebinix 800mg, Zebinix 1600mg
- Where
- South Korea
- Volunteers
- 50 people, healthy volunteers welcome
- Sponsor
- Whanin Pharmaceutical Company
Schizophrenia
Evaluating Safety, Tolerability and Pharmacokinetic of Multiple Ascending Doses of VV119
This study will consist of 2 parts: Part Ⅰ-in healthy adult subjects, Part Ⅱ-in adult patients with schizophrenia
- Trial name
- NCT06504290
- Testing
- VV119 （in healthy adult subjects）, VV119(in adult patients with schizophrenia)
- Where
- 4 sites in China
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- Vigonvita Life Sciences
Erectile Dysfunction
Phase 1 Study of SK3530 to Investigate of the Effect of Food
This study was designed to investigate the food effect of SK3530 on the pharmacokinetics (PKs).
- Trial name
- NCT00443625
- Testing
- SK3530
- Volunteers
- 15 people, healthy volunteers welcome
- Sponsor
- SK Chemicals Co., Ltd.
HBV Infection
A Phase I Clinical Trial to Evaluate HECN30227 Injection in Healthy Subjects and Subjects With Chronic Hepatitis B
To evaluate the safety, efficacy, pharmacokinetics and immunogenicity of single and multiple doses of HECN30227 Injection in healthy volunteers and patients with chronic hepatitis B
- Trial name
- NCT07771140
- Testing
- HECN30227 injection(SAD), HECN30227 injection (MAD)
- Where
- China
- Volunteers
- 78 people, healthy volunteers welcome
- Sponsor
- Sunshine Lake Pharma Co., Ltd.
Advanced Solid Tumors, Hepatocellular Carcinoma
A Multicentre, Open Label, Phase 1 Trial in Japan of the Mitogen Activated Protein Extracellular Signal Regulated Kinase (MEK) Inhibitor Pimasertib Given Orally to Subjects With Solid Tumors as Monotherapy
This is a two-part trial. "Solid tumor" in this protocol means solid tumor excluding hepatocellular carcinoma (HCC). Part 1: Dose Escalation Phase in subjects with solid tumor (Cohort A) and HCC (Cohort B).
- Trial name
- NCT01668017
- Testing
- Pimasertib
- Where
- Japan
- Volunteers
- 26 people
- Sponsor
- Merck KGaA, Darmstadt, Germany
Hepatitis C, Chronic, Hepacivirus
Three-year Follow-up of Participants After Administration of Boceprevir or Narlaprevir for the Treatment of Chronic Hepatitis C (P05063)
Study P05063 is a 3-year long-term follow-up (LTFU) study in participants previously treated with boceprevir (BOC) or narlaprevir (NAR) in a Phase 1, 2, or 3 clinical study.
- Trial name
- NCT00689390
- Testing
- Boceprevir, Narlaprevir, Peginterferon alfa-2b
- Volunteers
- 1,954 people
- Sponsor
- Merck Sharp & Dohme LLC
Leukemia, Myeloid, Acute, Refractory AML
Clinical Trial to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Tuspetinib (HM43239) in Patients With Relapsed or Refractory Acute Myeloid Leukemia
The main purpose of this study is to identify a safe and potentially effective dose of tuspetinib to be used in future studies in study participants diagnosed with acute myeloid leukemia (AML), myelodysplastic syndromes with…
- Conditions
- Leukemia, Myeloid, Acute, Refractory AML, Relapsed Adult AML, Myelodysplastic Syndrome With Excess Blasts-2
- Trial name
- TUSCANY (NCT03850574)
- Testing
- Tuspetinib, Venetoclax Oral Tablet, Azacitidine for Intravenous Infusion
- Where
- 34 sites in United States, Australia and 4 more
- Volunteers
- 240 people
- Sponsor
- Aptose Biosciences Inc.
Healthy
Clinical Trial to Assess Pharmacodynamic Effects on Segmental Endotoxin Induced Inflammatory Response of BI 1026706 Versus Placebo
The primary and secondary objectives of the current study are the assessments of anti-inflammatory pharmacodynamic effects on segmental endotoxin induced inflammatory response after 4 weeks treatment with BI 1026706.
- Trial name
- NCT02657408
- Testing
- BI 1026706
- Where
- Germany
- Volunteers
- 57 people, healthy volunteers welcome
- Sponsor
- Boehringer Ingelheim
Acute Myeloid Leukemia
Trial of PXD101 (Belinostat) in Combination With Idarubicin to Treat AML Not Suitable for Standard Intensive Therapy
An open-label, non-randomized, multi-centre, Phase I/II trial to assess the efficacy and safety of 2 schedules of PXD101 in combination with idarubicin in patients with AML not suitable for standard intensive therapy.
- Trial name
- NCT00878722
- Testing
- PXD101, idarubicin
- Where
- 6 sites in France, Germany and 1 more
- Volunteers
- 41 people
- Sponsor
- Valerio Therapeutics
Hepatitis C, Viruses
TMC435-TiDP16-C107: This Study Measures the (Possible) Influence of TMC435 on the Activity of a Selected Set of Drug-degrading Proteins by Measuring the Blood Levels of Drugs That Have Been Taken Together With TMC435 and That Are Known to be Specifically Degraded by These Drug-degrading Proteins.
The purpose of this study is to determine whether TMC435 influences the activity of certain drug-degrading proteins in the human body.
- Trial name
- NCT00866853
- Testing
- TMC435
- Volunteers
- 16 people, healthy volunteers welcome
- Sponsor
- Tibotec Pharmaceuticals, Ireland
Primary Malignant Brain Tumor
A Study of ABM-1310 in Patients With BRAF V600-Mutant Relapsed and Drug Resistant Primary Malignant Brain Tumors
Overall Design: This is a phase I, open-label, multicenter clinical study to evaluate the safety, tolerability, pharmacokinetics, and preliminary anti-cancer efficacy of ABM-1310 in patients with BRAF V600-mutant relapsed and…
- Trial name
- NCT05892653
- Testing
- ABM-1310
- Where
- 4 sites in China
- Volunteers
- 15 people
- Sponsor
- ABM Therapeutics Shanghai Company Limited
B-Cell Non-Hodgkin's Lymphoma (NHL), Lymphoma, Non-Hodgkins
T-Cell Therapy (EB103) in Adults With Relapsed/Refractory B-Cell Non-Hodgkin's Lymphoma (NHL)
This is an open-label, multi-center, Phase 1/2 clinical trial evaluating the safety and effectiveness of EB103 in R/R B-cell NHL patients with the highest unmet medical needs, such as Human Immunodeficiency Virus (HIV)-associated…
- Conditions
- B-Cell Non-Hodgkin's Lymphoma (NHL), Lymphoma, Non-Hodgkins, Lymphomas Non-Hodgkin's B-Cell, Non-Hodgkin Lymphoma
- Trial name
- STARLIGHT-1 (NCT06343311)
- Testing
- EB103
- Where
- 5 sites in United States
- Volunteers
- 27 people
- Sponsor
- Estrella Immunopharma, Inc.
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.